Cancer Treatment-Seattle Genetics

Clay Siegel is the Co-founder and the President, Chief Executive Officer and the Chairman of the Board of Seattle Genetics; he is also a Ph.D. holder. Clay Siegall is a scientist by professional, and he has a passion for helping others. His passion has led him to specialize on cancer therapies. Siegall wanted to achieve his passion for humanity and went ahead to establish Seattle Genetics.
Before the establishment of Seattle Genetics, Clay Siegall was working with Bristol-Myers Squibb Pharmaceuticals Research Institute from 1991 to 1997. Siegall has been very hardworking and has worked for several pharmaceuticals organizations including National Cancer Institute, and the National Institute of Health from 1988 to 1991. Siegel has a vast experience in the medical industry something that gave him a unique opportunity to serve on various boards including Ultragenyx Pharmaceuticals, Washington Roundtables, Alder Biopharmaceuticals, as well as Mirna Therapeutics where he served on the Board of Directors.
His determination and devotion have seen him getting recognized and being awarded including awards for the Alumina of the year in Mathematics, natural science as well as computer from the University of Maryland in 2013. The year before that is 2012 he was awarded the Pacific Northwest Ernst $ Young Entrepreneur of the year. Clay Siegall attended George Washington University for his Pd.D. in Genetics, and he graduated with Bachelors in Zoology from the University of Maryland. Clay Siegall is not only a medical professional, but he is also an author of some journals and holds around 15 patents.
Seattle Genetics is a biotechnology company which was established in 1998. The primary reason for founding the pharmaceutical organization was to develop as well as commercialize innovation on sanctioned anti-bodies drug for the treatment of cancer. Seattle Genetics can be described as a leading pharmaceutical company that deals with Anti-body Drug Conjugates (ADC) an advanced technology in the harnessing of the monoclonal antibodies that are meant to deliver cell- killing mediators that are distributed directly to the cancer cells. According to the Chief Executive Officer and the Co-founder of Seattle, who is also on the research team for the ADC, the drugs will spare the non-targeted cells, and this will lead to the reduction of non-toxic cells for the traditional method used for cancer treatment, chemotherapy. The company is also making efforts to discourse serious unmet medical needs.